Immunization with mRNA encoding tumor antigen is an emerging vaccine strategy for cancer. In this paper, we demonstrate that mice receiving systemic injections of MART1 mRNA histidylated lipopolyplexes were specifically and significantly protected against B16F10 melanoma tumor progression. The originality of this work concerns the use of a new tumor antigen mRNA formulation as vaccine, which allows an efficient protection against the growth of a highly aggressive tumor model after its delivery by intravenous route. Synthetic melanoma-associated antigen MART1 mRNA was formulated with a polyethylene glycol (PEG)ylated derivative of histidylated polylysine and L-histidine-(N,N-di-n-hexadecylamine)ethylamide liposomes (termed histidylated lipopolyplexes). Lipopolyplexes comprised mRNA/polymer complexes encapsulated by liposomes. The tumor protective effect was induced with MART1 mRNA carrying a poly(A) tail length of 100 adenosines at an optimal dose of 12.5 mg per mouse. MART1 mRNA lipopolyplexes elicited a cellular immune response characterized by the production of interferon-g and the induction of cytotoxic T lymphocytes. Finally, the anti-B16 response was enhanced using a formulation containing both MART1 mRNA and MART1-LAMP1 mRNA encoding the antigen targeted to the major histocompatibility complex class II compartments by the lysosomal sorting signal of LAMP1 protein. Our results provide a basis for the development of mRNA histidylated lipopolyplexes for cancer vaccine.
Introduction
Immunization of patient with genetic material encoding tumor antigen or with genetically modified dendritic cells (DCs) expressing tumor antigen are emerging vaccine strategies for cancer. [1] [2] [3] [4] [5] Ensuring induction of tumor antigen-specific CD8 þ cytotoxic T lymphocytes (CTLs) is one of the major goals of cancer immunotherapy. CTLs are induced when antigens are presented by major histocompatibility complex (MHC) class I molecules to the T-cell receptors of CD8 þ T cells. The activated CTLs re-circulate through lymphoid organs and peripheral tissues in search of cells expressing the same antigen and lyse tumor cells directly. However, the role of CD4 þ T cells in anti-tumor immunity is well established. 6 Introduction of genetic material encoding tumor antigen into DCs will allow antigen expression in its native state, will direct presentation of all epitopes via MHC class I pathway and will induce tumor antigen-specific CTLs. For this purpose, in vitro transcribed (IVT) mRNA encoding tumor antigen instead of DNA as a nucleic acid-based strategy offers several advantages. First, translation of mRNA is of frequent occurrence in the cytosol, mRNA are quickly translated in all cell types and allow a transient expression of the antigenic protein over a limited time (for example, a few hours). Therefore, the delivery of IVT mRNA into the cytosol of non-dividing cells such as DCs would be easier and sufficient than the delivery of plasmid DNA in the nucleus. Furthermore, there is no uncontrolled long-term expression of the antigen as might occur upon integration of DNA vaccine in the cell genome, which could induce deregulation in gene expression and eventually lead to tumors. Moreover, synthetic mRNA do not bear any regulatory nucleic sequences (promoters, terminators, enhancer, and so one) and no antibiotic-resistance nucleic sequences are injected in the vaccinated population. Recently, it has been clearly demonstrated that cellular and humoral antitumor responses can be induced by DCs transfected with either mRNA from tumor cells or IVT mRNA of tumor-activated antigen. 7, 8 Although cellular immunotherapy using DCs transfected with DNA or mRNA encoding antigen still requires improvements, this approach will remain expensive and patient-dependent. Therefore, direct injection of tumor antigen mRNA constitutes a good alternative for antitumor vaccine delivery. Protein expression and triggering of immunity have been reported in mice by intramuscular [9] [10] [11] [12] [13] and gene gun injection 14 of naked mRNA encoding reporter proteins or tumor antigens. Despite promising results obtained in animal models, the usefulness of intra-muscular or -dermal immunization (which is more comfortable than systemic administration) with naked mRNA or DNA encoding antigen remains uncertain for humans and needs improvements. The advantage of systemic injection lies in the possibility of antigen delivery in lymphoid organs that contain all immune cell types necessary to induce a protective antitumor immune response.
We have designed histidine-rich cationic polymers and histidylated cationic lipids, which are efficient vectors in transfecting various cell types. [15] [16] [17] These histidylated vectors exert high cytosolic DNA delivery presumably through enhanced fusion with anionic lipid components of the endosomal membranes at lower acidity. We have also reported that anti-reverse cap analogue (ARCA)-mRNA-A100, a mRNA construct capped with 3 0 -O-methylm7 5 0 Gppp 5 0 G and terminated by a Poly(A) tail of 100 adenosines, provides a high level of protein expression. 18 Here, we report on the use of the above-mentioned synthetic mRNA encoding the human melanoma MART1 (MelanA) antigen and histidylated vectors in immunizing mice against B16F10 melanoma. Human MelanA/MART1 antigen shares a 68.6% amino-acid sequence identity with its murine counterpart, 19 and it has been found to induce an immune response against the murine B16 melanoma. [20] [21] [22] Our data showed that systemic injections of MART1 mRNA formulated only with polyethylene glycol (PEG) ylated histidine-rich polylysine and histidylated liposomes (termed lipopolyplexes) delayed significantly the growth of B16 melanoma. This protective effect varied with mRNA dose and poly(A) tail length. The immune response was characterized as a CTL-mediated anti-B16 melanoma response. Importantly, a formulation containing both MART1 mRNA and sig-MART1-LAMP1 mRNA encoding the antigen targeted to the MHC class II compartments by the lysosomal sorting signal of human LAMP1 protein has been shown to enhance tumor protection.
Materials and methods
All reagents were purchased from Sigma (St Quentin Fallavier, France) unless stated otherwise.
Animals and cell lines
Nine to 11-week-old C57BL/6 adult mice were bred in a specific pathogen-free animal facility. Mice were kept in isolated ventilated cages, and all experiments complied with the French Government's Ethical and Animal Experiment Regulations. B16/F10 cells (ATCC CRL 6475) were maintained in Dulbecco's modified Eagle's medium (Life Technologies, Cergy Pontoise, France) containing 10% heat-inactivated fetal bovine serum (FCS), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 U/ml streptomycin (all from Life Technologies).
Plasmids pGEM-4Z/MART1/A64 and pGEM-4Z/sig-MART1-LAMP1/A64 plasmids DNA encoding the human MelanA/MART1 melanoma antigen under the T7 RNA polymerase promoter of l-bacteriophage were kindly given by Dr A Bonehill and Dr K Thielemans (Medical School of the Vrije Universiteit Brussels, Brussels, Belgium). 23 pGEM-4Z/sig-MART1-LAMP1/A64 encodes the chimeric MART1 protein carrying the peptide signal and lysosomal sorting signal of human LAMP1 protein, which have high homology with those of mice. 24, 25 pGEM-4Z/LUC/A64 encoding the firefly Luciferase gene (LUC) under the T7 RNA polymerase promoter of l-bacteriophage was constructed as described previously. 18 pCMV-MART1 plasmid DNA encoding the human MelanA/MART1 antigen under control of the human cytomegalovirus promoter (CMV) was a kind gift from Dr Van den Eynde (Ludwig Institute for Cancer Research, Brussels, Belgium). Plasmids were propagated in DH5a supercompetent Escherichia coli (Invitrogen, Cergy Pontoise, France) and purified on endotoxin-free Qiagen-tip 500 columns (Qiagen SA, Courtaboeuf, France).
In vitro mRNA transcription Plasmids were linearized with SpeI (Invitrogen) and used as DNA templates for the in vitro transcription reaction. 18 Briefly, ARCA mRNA were obtained after transcription with the T7 mMessage mMachine kit (Ambion, Oxfordshire, UK) allowing a capping with 3 0 -O-methyl m7 G and polyadenylation was performed with the Poly(A) tailing kit (Ambion). mRNA was purified by DNAse I digestion, followed by phenol/chloroform/ isoamylic alcohol extraction and isopropanol precipitation. mRNA were dissolved at 1 mg/ml in RNAse-free water. The quality was checked by 1% agarose gel electrophoresis on mRNA denaturation at 651C for 10 min in formaldehyde-glycerol loading buffer. The RNA concentration was determined by absorbance at 260 nm using 1UA ¼ 40 mg/ml. RNA was stored at À801C in small aliquots in polypropylene cryotubes.
PEG-HpK
Histidylated polylysine (HpK) (250 mg; 3.5 mmol in 3 ml dimethyl sulfoxide) prepared as previously described 26 was coupled with a polyethylene glycol (PEG) molecule of 5 KDa upon reaction for 4 h at 201C with the N-hydroxysuccinimide derivative of the mPEG-propionic acid (29 mg; 5 mmol) (mPEG-SPA, Shearwater, Huntville, AL) in the presence of N,N-diisopropylamine (116 ml; 850 mmol). The polymer was precipitated in ethyl acetate, spun down by centrifugation (1800 g for 15 min), solubilized in distilled water and freeze-dried. About one PEG molecule was bound per polymer molecule as calculated from the 1 H NMR peak intensity ratio of the methylene protons at 3.5 p.p.m. of PEG to those of the lysyl side chain at 1.2-1.3 p.p.m.
HDHE:chol liposomes
A lipid film was prepared under nitrogen by drying 1 ml of an ethanol solution of 5.4 mM of L-histidine-(N,N-di-nhexadecylamine)ethylamide (HDHE) and cholesterol (chol) (molar ratio of 1:2). 16 The film was hydrated with 1 ml sterile RNase-free water (Sigma), vortexed for 3 min and kept for 2 h at 41C. The mixture was then vortexed and sonicated for 15 min at 37 kHz using a Bioblock ultrasonic bath (Bioblock Scientific, Illkirch, France).
Endotoxin
The presence of endotoxin in polymer, lipids and mRNA was less than 0.1 EU/ml as evaluated by Limulus Amebocyte lysate test method using QCL-1000 kit (Cambrex, Walkersville, MD).
Polyplexes, lipoplexes and lipopolyplexes preparation
Formulations were prepared in polypropylene tubes. mRNA (1 mg/ml) samples were made up to 150 ml with RNase-free water. Polyplexes were prepared at an RNA/polymer ratio of 1:3 (mg:mg) by adding PEG-HpK (75 mg in 50 ml water) to mRNA or pDNA (25 mg in 125 ml water), mixed for 4 s and kept for 30 min at 201C. Lipoplexes were obtained at an RNA/lipids ratio of 1/2 (mg:mg) by adding mRNA (25 mg in 125 ml water) to 25 ml liposomes (50 mg in 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, pH 7.4) and the solution was kept for 15 min at 201C. Lipopolyplexes were formed at an RNA/polymer/lipids ratio of 1:3:2 (mg:mg:mg) by adding liposomes (25 ml; 50 mg) to the polyplex preparation, mixed gently and kept for 15 min at 201C. For injection in mice, the solutions were diluted to 320 ml with water and adjusted to 0.15 M NaCl with a 3 M NaCl solution.
Transmission electron microscopy TEM measurements were carried out by means of a LEO-Zeiss 902 electron microscope operating at 80 kV, equipped with an electron spectrometer filtering out inelastic electrons for better imaging. Five microlitre of mRNA or polyplexes was deposited over glow-discharged carbon-coated copper grids activated with pentylamine, washed with 2% uranyl acetate, blotted and dried. For liposomes and lipopolyplexes, 5 ml of samples were deposited on glow-discharged carbon-coated copper grids, and a negative contrast staining was done with 10 ml of 2% aqueous phosphotungstic acid solution (pH adjusted to 7.3 using 1 N NaOH). Observation was done in the dark-field mode.
Tumor challenge experiments Polyplexes, lipoplexes, lipopolyplexes or NaCl 0.9% were injected twice at 1-week interval into the tail vein of the mice. One week after the second injection, mice were challenged subcutaneously in the back with 10 5 B16/F10 cells in 100 ml of phosphate-buffered saline (PBS). Mice were monitored every 2 days and tumor size was measured using a calliper. Tumor volume (V) was expressed as the half of the square of the smallest diameter (l) multiplied by its largest diameter (L):
Animals that developed tumors with L410 mm were euthanized for ethical reasons. Lung metastases were generated by intravenous injection of 10 5 B16/F10 cells in 100 ml of PBS 1 week after the second immunization. Mice were killed 14 days after challenge, and the number of macroscopically visible melanoma metastases on the surface of the lungs was counted and measured in a masked manner by two different experimenters.
CTL response
Single cell suspensions from afferent lymph node (LN) and spleen from mice were obtained 7 days after immunization by passing on Histopaque 1.083 gradient. Freshly isolated cells (10 7 cells) were restimulated by cocultured at 371C in 6-well plates with B16/F10 cells (10 6 cells) previously inactivated by incubation for 1 h at 371C in the presence of 50 mg/ml mitomycin C. Cells were cultured in 5 ml RPMI-1640 medium containing 10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 1 mM amino acids, 100 U/ml penicillin/streptomycin (all from Life Technologies) and 50 U/ml mouse recombinant IL-2 (R&D Systems, Minneapolis, MN).
The CTL response was measured after 3 days restimulation. Serial dilutions of effectors (splenocytes and LN cells) were incubated in triplicate for 5 h at 371C and 5% CO 2 in the presence of 5 Â 10 3 untreated B16/F10 cells (target cells) in 100 ml medium in 96-well, U-bottomed plates. The cytotoxicity of the supernatant was then measured by using the lactate dehydrogenase colorimetric assay according to the manufacturer's instructions (CytoTox 96 Non-Radioactive Cytotoxicity Assay, Promega, Charbonnie`res, France). Briefly, supernatants (50 ml) were mixed with 50 ml of reconstituted substrates in each well of a 96-well plate and the incubation was carried out for 30 min at room temperature in the dark. The absorbance at 490 nm was measured using a microplate spectrophotometer (1420 Multilabel Counter Victor, Wallac, Evry, France). The percentage of lysis was calculated from the formula: 100 Â (SÀM)/(WÀM), where M and S were the absorbance in the presence of the medium alone and of the supernatant, respectively. W was the maximum release determined by adding 10 ml of Triton X-100 lysis solution before collecting supernatant.
IFN-g secretion
Freshly isolated LN and spleen cells (10 7 cells) were cocultured with 10 6 B16/F10 cells for 20 h at 371C in 6-well plates. The interferon-g (IFN-g) secretion assay was performed using Miltenyi Biotec mouse IFN-g secretion mRNA-based cancer vaccine M Mockey et al assays detection kit according to the manufacturer's protocol (Miltenyi Biotec, Paris, France). Non-adherent cells were collected and washed with PBS containing 0.5% bovine serum albumin and 2 mM ethylenediaminetetraacetic acid (pressurized fluid extraction, PSE). Cells (10 6 ) were incubated for 10 min at 41C in cold culture medium containing 10 ml of IFN-g catch reagent. Coated cells were then incubated for 45 min at 371C in 1 ml medium. After several PSE washings, cells were incubated for 10 min at 41C in PSE containing fluorescein-labeled anti-mouse CD4 antibodies (clone GK1.5, Miltenyi Biotec) diluted 10 times or fluorescein-labeled anti-mouse CD8 antibodies (clone 53-6.7, BD Pharmingen, San Diego, CA) diluted 100 times and phycoerythin-labeled anti-mouse IFN-g antibodies (Miltenyi Biotec) diluted 10 times. The cell fluorescence intensity was analyzed by flow cytometry. The lymphocyte population was gated on the forward scatter and side scatter, and fluorescence intensity of 10 000 cells was measured at 520 and 585 nm upon excitation at 488 nm.
Statistical analysis
Statistical evaluation of differences between experimental groups was determined by Mann-Witney U-test for nonviral vectors comparison experiments and Student's t-test for other data using Prism software. Po0.05 were statistically significant.
Results

MART1 mRNA formulations
The synthetic ARCA-MART1-A100 mRNA with an homogenous size of 850 bases contained the T7 transcription initiation, the multiple cloning sites of the 5 0 -untranslated region (60 nucleotides) followed by the coding region for MART1 (690 nucleotides) and the 100 adenosines representing the poly(A) stretch nucleotides at its 3 0 -untranslated end (Figure 1a inset). Findings in electron microscopy indicated that mRNA molecules exhibited a faint contrast and appeared as small fragments with sometimes small microaggregates ( Figure 1a ). This mRNA shape is a typical feature of a single-stranded nucleic acid molecule. 27 mRNA polyplexes were formed with PEG-HpK at a mRNA/polymer weight ratio of 1:3 (mg:mg). As shown in Figure 1b , small aggregates of B50 nm in diameter were observed due to interaction between mRNA and PEG-HpK. These aggregates were dense and spherical as those observed for poly(A) and NCp7. 27 HDHE:chol liposomes appeared as unilamellar vesicles of 60-100 nm in diameter (Figure 1c) . Ternary complexes between mRNA, PEGHpK and liposomes (termed lipopolyplexes) were prepared by mixing liposomes with mRNA/PEG-HpK polyplexes at an mRNA/polymer/lipids weight ratio of 1:3:2 (mg:mg:mg). TEM analysis showed that the mixture of polyplexes with liposomes led to vesicles of 60-100 nm in diameter with a dense core in their middle presumably corresponding to mRNA polyplexes entrapped inside liposomes (Figure 1d ). Empty vesicles corresponding to the excess of liposomes were also present in the mixture, but free polyplexes were not observed.
Inhibition of B16 melanoma growth by MART1 mRNA lipopolyplexes vaccination Twenty-five micrograms of either naked MART1-mRNA or the above-mentioned MART1-mRNA formulations were intravenously injected in mice on days 0 and 7. LUC mRNA (ARCA-LUC-A100) encoding luciferase was used as irrelevant mRNA, and similar formulations containing this mRNA were also injected as controls. At day 14, mice were subcutaneously challenged with 10 5 B16/ F10 cells and the tumor growth was measured every 2 days up to 28 days post-mRNA injection. In control mice, the tumor volume increased with time and reached a large volume of B600 mm 3 at day 28 ( Figure 2a) . A protective effect against the tumor growth occurred in mice receiving MART1 mRNA lipopolyplexes. This protective effect was specific and dependent on the mRNA sequence, because there was no significant difference between control mice and mice which have received LUC mRNA lipopolyplexes. Figure 2b summarizes the tumor volume at day 26 as a function of injected mRNA formulations. Neither naked MART1 mRNA nor MART1 mRNA complexed with PEG-HpK or HDHE:chol liposomes had significant effect on the tumor growth compared to the control group. An inhibition of the tumor proliferation was clearly obtained, when mice received MART1 mRNA complexed with both PEG-HpK and HDHE:chol liposomes. Altogether, these results indicated that systemic injections of MART1 mRNA lipopolyplexes induced a specific and significant protection against B16 melanoma growth.
We then assessed whether those mRNA lipopolyplexes could also protect mice from lung metastases. Seven days after the second injection of mRNA lipopolyplexes, mice were intravenously challenged by 10 5 B16/F10 cells known to promote lung invasion. Mice were killed 14 days later, the lungs removed, and macroscopically visible metastasis counted and measured. As shown in Figure 3 , immunization with MART1 mRNA lipopolyplexes drastically reduced by ca 75%, the total number of lung metastases. In the control group (LUC mRNA lipopolyplexes), a mean of 119 (713) melanoma lung metastases was counted versus 29 (715) in the MART1 mRNAtreated group. The reduction of the metastasis number did not affect the size distribution of metastases between those two groups. Indeed, 80% (710) of small metastases (o2 mm) were found in the control group and 73% (76) in the MART1 group. Overall, these data showed that the immunization with MART1 mRNA lipopolyplexes was also able to reduce lung metastasis formation.
Influence of mRNA Poly(A) tail length on tumor protective effect The length of the Poly(A) tail of mRNA which is important for the translation and the stability of mRNA could influence the level of the antigenic protein production and consequently antigen presentation and the immune response. Indeed, we have reported that mRNA-lipofection of DCs was more efficient with mRNA-based cancer vaccine M Mockey et al mRNA containing a poly(A) tail length of 100 adenosine residues than that with 64 adenosine residues. 18 Thus, we investigated the influence of the Poly(A) tail length of MART1 mRNA on the protection against B16 melanoma. Mice were immunized with lipopolyplexes containing MART1 mRNA bearing a poly(A) tail of 100 adenosines (ARCA-MART1-A100) or 64 adenosines (ARCA-MART1-A64). It is worth to mention that these two mRNA have a free A at the end of their poly(A) tail. Indeed, poly(A) tail extension with another nucleotide than A decreased significantly the protein level. 28 As shown in Figure 4 , the protection was more efficient with ARCA-MART1-A100 than with ARCA-MART1-A64, indicating that the effectiveness of the immunization was strictly dependent on the mRNA Poly(A) tail length. Thus, the following experiments were conducted with ARCA-MART1-A100.
Effectiveness of mRNA versus DNA vaccine
The protection effect of MART1 mRNA was further compared to that of a plasmid DNA (pCMV-MART1) encoding MART1 antigen. Data in Figure 4 show that no significant tumor growth inhibition was obtained after administration of pCMV-MART1 lipopolyplexes indicating that mRNA-based vaccination holds more potential than DNA vaccination in cancer immunotherapy.
Optimization of the MART1 mRNA dose administration Dose-response experiments were performed to check the influence of the amount of MART1 mRNA. Mice were vaccinated with lipopolyplexes containing 6.25, 12.5, 25 or 50 mg of ARCA-MART1-A100 ( Figure 5) . A significant inhibition of the tumor volume was obtained with a dose of 12.5 mg ARCA-MART1-A100 mRNA per mouse.
Induction of a cellular immune response by MART1 mRNA lipopolyplexes vaccination Cytotoxicity and IFN-g secretion assays were conducted to find whether MART1 mRNA immunization induced cellular immune response priming. Seven days after the second injection of mRNA lipopolyplexes, splenocytes and afferent LN cells were collected and restimulated The cytotoxicity assay showed that anti-B16 CTLs were specifically generated following MART1 mRNA lipopolyplexes vaccination ( Figure 6 ). Indeed, no lysis activity was obtained with splenocytes and afferent LN cells from the LUC mRNA and control groups. The measurement of IFN-g secretion by T cells further confirmed this induction of a CTL immune response. After 20 h restimulation by B16/F10 cells, a positive IFN-g staining was observed in CD8 þ and CD4 þ T cells from mice treated with MART1 mRNA lipopolyplexes, whereas no significant IFN-g labeling was detected in cells isolated from mice treated with LUC mRNA lipopolyplexes ( Table 1) . As shown in Figure 7 , in the MART1 group, 3.5% (71.1) and 3.8% (70.9) of total LN isolated cells were CD4 þ and CD8 þ IFN-g-positive T cells, respectively. In spleen of the MART1 group, these proportions were 2.3% (70.2) and 5.9% (71.2) of the total splenocytes, respectively. Altogether, these data indicated that immunization by systemic injection of MART1-mRNA lipopolyplexes induced an anti-B16-specific CTL immune response.
Synergic effect of MHC class I and class II presentation pathways MART1 mRNA lipopolyplexes elicited a CTL immune response indicating that MART1 follows the MHC class I presentation pathway. Indeed, MelanA/MART1 is a type III signal-anchor protein that is mainly localized at the endoplasmic reticulum and the transGolgi network. 29 We wanted to check if the targeting of MART1 to organelles permitting its presentation via MHC class II could also induce a significant B16 protection. For this purpose, mice were injected with lipopolyplexes containing 12.5 mg of the ARCA-A100 mRNA version of sig-MART1-LAMP1 corresponding to MelanA/MART1 mRNA 
Discussion
Data from this study show that 12.5 mg of MART1 mRNA histidylated lipopolyplexes were able to induce an anti-B16 specific cellular immune response and the protection of mice against B16F10 melanoma growth. No immune response as well as anti-tumor protection was obtained with lipoplolyplexes containing the irrelevant LUC mRNA. Moreover, the reduction of B16 lung metastasis validates the strength of the melanoma growth protection with MART1 mRNA lipopolyplexes. Compared to previous reports, the originality of this study lies in the use of a new mRNA formulation, the tumor model and the route of vaccine delivery. Indeed, we deliberately investigated the vaccine effect on a B16F10 tumor model, which is highly aggressive and the intravenous route was chosen to deliver the vaccine. This delivery way was dictated by (i) the fact that an intrasplenic delivery of mRNA encoding gp100 complexed with HJV liposomes has been shown to induce an immune response against B16F1 tumor growth 30 and (ii) our unpublished data showing that histidylated lipopolyplexes did reach the spleen following intravenous injection. Therefore, the intravenous injection for our formulation is an efficacious and less invasive way than intrasplenic injection.
We have exploited the combination of a pH-sensitive histidylated polymer and pH-sensitive liposomes to form mRNA lipopolyplexes. First, mRNA was condensed in small particles with PEGylated histidylated polylysine before adding HDHE liposomes. As observed by TEM, this combination results in a formulation comprising mRNA polyplexes entrapped in liposomes. The presence of PEG molecule on the cationic polymer reduced the cationic charges of polyplexes. 31 Therefore, repulsive forces between polyplexes and cationic liposomes are reduced favoring PEG-polyplexes entrapment by the cationic liposomes. 32 The benefit of this formulation may result in both mRNA protection against degradation and the synergic effect of the histidylated vectors to mediate endosome escape of mRNA inside antigenpresenting cells (APCs) in a pH-sensitive manner.
Lipopolyplexes made with 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP):chol liposomes plus protamine sulfate or dioleoyl phosphatidylethanolamine (DOPE):cholesteryl hemisuccinate liposomes plus polylysine have been first developed by L Huang and were mainly used for DNA delivery. 32, 33 Concerning mRNA vaccination, lipopolyplexes prepared with 30 mg mRNA encoding E coli b-galactosidase (LacZ) condensed with protamine plus unifectin cationic liposomes have been found to induce CTL and humoral immune responses against cells expressing LacZ following intravenous injection in mice. 13 It is worth mentioning that LacZ mRNA complexed with unifectin cationic liposomes or with protamine were inefficient to induce an immune response when injected intravenously In our study, we have also observed that MART1 mRNA complexed with PEG-HpK or with HDHE:chol liposomes were inefficient. Yet, some reports have described mice immunization with mRNA lipoplexes. A influenza virusspecific CTL activity have been obtained with chol/ phosphatidylcholine/phosphatidylserine liposomes containing mRNA encoding influenza virus nucleoprotein. 34 In the B16 tumor model, HVJ liposomes containing gp100 mRNA have been found to protect mice against B16F1 melanoma. 30 In this case, the vaccine was introduced directly into the spleen, and the B16F1 cell line is a less aggressive than the B16/F10 cell line used in our study. In another model, DOTAP:DOPE liposomes complexed with 3 mg of ovalbumin mRNA have been reported to induce a specific immune response upon intravenous injection. 35 However, the efficiency of mRNA vaccination in priming anti-ovalbumin CTLs depended on the liposome composition. Indeed, liposomes made with either DOTAP without DOPE or 1,3-di-oleoyloxy-2-(6-carboxy-spermyl)-propylamid (DOSPER) were not efficient compared to DOTAP:DOPE liposomes.
The immunization efficiency may depend on the injection route and the mRNA formulation. Hoerr et al. 13 have reported that a single intradermal injection into the mice ear pinna of 1 mg of protamine-condensed LacZ mRNA or 30 mg unprotected lacZ mRNA triggered a specific CTL immune response against cells expressing LacZ, while the naked mRNA and the protamine condensate mRNA were inefficient upon systemic injection. However, the CTL activity was lower than that obtained upon intravenous injection of mRNA/ protamine/unifectin lipopolyplexes. In the same line, the intradermal delivery of 2 mg naked TRP2-enhanced green fluorescent protein (EGFP) mRNA in the skin by gene gun provided immunization against the B16 tumor model.
14 APCs reached by the intradermal route are mainly resident DCs (that is Langerhans DCs) that must migrate to LNs to trigger an optimal T-cell responses. The systemic injection is less comfortable than intramuscular or intradermal route, but this route offers the possibility to deliver mRNA into lymphoid organs that contain all immune cell types necessary to induce an efficient immune Lipid-protamine-DNA complexes have been found to be distributed to all major organs including liver and spleen upon intravenous injection in mice. 36 We have also found that DNA was distributed into the liver and the spleen when DNA histidylated lipopolyplexes were injected in mice (unpublished data). On this basis, MART1 mRNA lipopolyplexes may be captured by hepatic and splenic APCs. However, the delivery of MART1 mRNA in other circulating immune cells such as plasmacytoid DCs (pDCs) or monocytes cannot be excluded. The capacity of pDCs themselves to present exogenous antigens is not fully demonstrated, but it has been reported that activated pDCs may induce expansion of antigen-specific memory CD8 þ T cells and Th1 CD4 þ T cell populations specific for the MART1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] epitope. 37 In addition, it has been suggested that pDCs may induce maturation of local 
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B16 protection was higher when MART1 mRNA carried a Poly(A) tail of 100 adenosine residues than one carrying 64 adenosine residues. This in vivo result is in agreement with our findings on mRNA lipofection of DCs with MART1 and LUC mRNA. 18 These results are also in line with a recent systematic investigation on the impact of the poly(A) tail length on the transfection efficiency of DCs, which showed that EGFP mRNA with a poly(A) tail length of 120 A was superior to EGFP mRNA with a poly(A) tail length of 67A. 28 Increasing mRNA stability/transational activity would improve the transfection efficiency of DCs as well as the antigen presentation. To elongate the poly(A) tail of ARCA-MART1-A100, the enzymatic polyadenylation cannot be used. Indeed as shown by Holtkamp et al., 28 the enzymatic polyadenylation of mRNA with a poly(A) tail length of 120A resulted in mRNA with poly(A) tail lengths of different sizes whereas IVT mRNA from vectors encoding long poly(A) tail produced a single size mRNA. Therefore, vectors encoding long poly(A) tail would be preferred to synthesize mRNA with longer poly(A) tail length. The length of the poly(A) is an important parameter for RNA stability and translation activity but it could be also benefit to insert human b-globin 3 0 untranslated regions known to stabilize mRNA. 13, 39 Recently, the insertion of two sequential b-globin 3 0 untranslated regions between the coding region and the poly(A) tail of 120A enhanced protein level and persistence of the protein in DCs. 28 We cannot exclude the possibility of immune system activation by the primary and secondary structures of mRNA via TLR3, TLR7 and TLR8 Toll-like receptors of DCs. [40] [41] [42] [43] [44] [45] [46] Similar contribution from MART1 mRNA lipopolyplexes could be explored using gene-deficient mice. In our system, the effect of MART1 mRNA immunization was much higher than of MART1 DNA immunization because DNA transfection of APC requires the plasmid import in the nucleus. To date, as the majority of synthetic vectors, histidine-rich vectors did not achieve an efficient nuclear delivery of plasmid DNA in non-dividing cells.
Taken together, our data indicate that a CD8 þ and CD4 þ T-cell activation was specifically induced by MART1 mRNA lipopolyplexes leading to an anti-B16 melanoma response. CD4 þ T-helper cells play also a key role in the establishment of the CTL response. [47] [48] [49] MART1 mRNA lipopolyplexes also induced CD4 þ IFN-g-positive T cells. There are growing bodies of evidence showing that in humans one epitope of MART1 can be presented via MHC class II leading to a stimulation of CD4 þ T cells inducing a IFN-g secretion. [50] [51] [52] The epitope recognized by human melanoma reactive CD4 þ T cells is MART1 peptide that is strictly conserved in mouse MART1. Despite MART1 mRNA lipopolyplexes induced CD4
þ IFN-g-positive T cells, the induction might be too weak to help the CTL response. There are several lines of evidence showing that the targeting of antigens carrying the LAMP1 lysosomal signal to the MHC class II pathway mediates a specific CD4 þ T-cell response. The transfection of DCs with sig-MelanA-LAMP1, sig-MAGE-LAMP1 and sig-carcinoembryonic antigen (CEA)-LAMP1 mRNA encoding chimeric MART1, MAGE and CEA have been shown to promote induction of an antigen-specific CD4 þ T-cell response. [53] [54] [55] The vaccination of mice with DNA encoding sig-E7-LAMP1-16 have generated simultaneous CD4 þ and CD8 þ T-cell responses against the human papillomavirus. [56] [57] [58] Lastly, the injection of DCs transfected with the telomerase reverse transcriptase-LAMP1 mRNA has led to an enhancement of antigen-specific CD4 þ and CD8 þ T cells against metastatic prostate cancer in humans. 59 In contrast with the above-mentioned data, we found that the injection of sig-MART1-LAMP1 mRNA lipopolyplexes did not protect mice against B16 melanoma, but induction of an anti-MART1 immune response upon a systemic injection of sig-MART1-LAMP1 mRNA in mice has never been reported previously. The high protective effect obtained with the combination of ineffective doses of both MART1-and sig-MART1-LAMP1 mRNA suggests that the immune response may be improved by enhancement of the CD4 þ T-cells activation. A comparative measurement of the CD4 and CD8 induction upon immunization with MART1 mRNA alone or MART1 mRNA plus MART1-LAMP1 mRNA will bring mechanistic explanations on this synergic effect.
In conclusion, MART1 mRNA lipopolyplexes made with the PEGylated histidine-rich polylysine and histidylated liposomes are promising and potent tumor vaccine upon systemic injection. Increasing mRNA dose above 12.5 mg did not improve the effect in terms of tumor growth delay, suggesting that an optimal immune mRNA-based cancer vaccine M Mockey et al response was reached with this mRNA formulation. The addition of MART1 targeted to MHC class II presentation pathway can be proposed to increase the immune protection. Moreover, the activation of the innate immunity by powerful adjuvant as TLR nucleotide agonists will be of further help to enhance the immune defense. [60] [61] [62] [63] 
